Article Figures & Data
Figures
- Figure 1.
Use of U-500 Insulin in Obese Patients With Type 2 Diabetes
BMI=body mass index; T2D=type 2 diabetes;
Reproduced from Davidson MB et al. U-500 Regular Insulin: Clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients. Diabetes Care 2010;33(2):281–283. With permission from the American Diabetes Association.
- Figure 2.
Effect of Degludec U200 Versus Glargine U100 on Glucose Levels
IDeg=insulin degludec; IGlar=insulin glargine; SMBG=self-monitoring of blood glucose.
Reproduced from Gough SCL et al. Low-Volume Insulin Degludec 200 units/mL Once Daily Improves Glycemic Control Similar to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial. Diabetes Care 2013; doi:10.2337/dc12-2329. With permission from the American Diabetes Association.
- Figure 3.
Glucose-Lowering Effect of Capsulin in T2DM
Reproduced from Luzio SD et al. The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes Obes Metab 2010;12(1)82–87. With permission from John Wiley and Sons.
- Figure 4.
Glycemic Control After 8 Weeks of LY2605541 Versus Glargine in Type 1 Diabetes
Reproduced from Rosenstock J et al. Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study. Diabetes Care 2013;36:522–528. With permission from the American Diabetes Association.
Tools
Table of contents
Cited By...
- No citing articles found.